Chemotherapy-induced nausea and vomiting

What it is

Chemotherapy-induced nausea and vomiting (CINV) is nausea or vomiting caused by cancer chemotherapy, with acute symptoms often starting within 24 hours. The key practical fact is that CINV is often preventable when anti-nausea medicines are given before chemotherapy based on the regimen's emetogenic risk, meaning how likely it is to cause vomiting.

CINV is not one single pattern. It includes several clinical types that differ by timing and response to treatment. Good prevention matters because uncontrolled nausea and vomiting can lead to dehydration, poor food intake, missed chemotherapy, anxiety about future cycles, and lower quality of life.

A simple way to classify CINV is:

Type	Typical timing
Acute	Within minutes to 24 hours after chemotherapy
Delayed	More than 24 hours after chemotherapy, often days 2-5
Anticipatory	Before treatment, usually after a bad prior experience
Breakthrough	Happens despite preventive medicines
Refractory	Continues in later cycles after prior antiemetic failure

Some chemotherapy drugs have high emetogenic potential, while others have moderate, low, or minimal risk. Cisplatin is a classic example of a highly emetogenic drug. In routine oncology care in India as elsewhere, antiemetic plans are usually matched to the chemotherapy protocol rather than chosen casually cycle by cycle.

How it works

CINV happens because chemotherapy can activate both gut and brain pathways involved in nausea and vomiting. One important early pathway is serotonin release from the gastrointestinal tract, which stimulates 5-HT3 receptors and triggers vomiting signals. Another major pathway involves substance P acting at neurokinin-1, or NK1, receptors, which is especially relevant for delayed symptoms.

This is why modern antiemetic treatment often combines drugs that block different pathways rather than relying on one medicine alone. Common classes include:

1. 5-HT3 receptor antagonists such as ondansetron, granisetron, and palonosetron
2. NK1 receptor antagonists such as aprepitant or fosaprepitant
3. Corticosteroids such as dexamethasone
4. Other agents such as olanzapine for selected patients or difficult-to-control symptoms

Nausea is often harder to control than vomiting. That is an important point for patients, because someone may not vomit but can still have clinically significant CINV. Anxiety, prior bad experiences, motion sickness history, and expectation of nausea can also contribute, especially in anticipatory CINV.

Evidence and uses

The strongest evidence supports prevention rather than waiting for symptoms to start. Clinical reviews and guideline-based care show that antiemetic prophylaxis works best when it is chosen according to the emetogenicity of the chemotherapy regimen.

For highly emetogenic chemotherapy, standard prevention commonly includes a combination of a 5-HT3 receptor antagonist, dexamethasone, and an NK1 receptor antagonist. In many modern protocols, olanzapine is also added for some patients, especially when nausea control is a concern. For moderately emetogenic chemotherapy, two or more drugs are often used, depending on the exact regimen. Lower-risk regimens may need less intensive prevention.

A brief comparison is useful:

Chemotherapy risk	Typical prevention approach
High emetic risk	Usually 3-drug or 4-drug prophylaxis
Moderate emetic risk	Usually 2-drug or selected 3-drug prophylaxis
Low emetic risk	Usually 1 drug, often dexamethasone or another guideline-based option
Minimal emetic risk	Routine prophylaxis may not be needed

Behavioral approaches can also help, especially for anticipatory symptoms. Relaxation training, guided imagery, and related supportive methods have shown benefit in some studies. These methods do not replace antiemetic medicines for high-risk chemotherapy, but they may reduce distress and improve coping.

In practice, the most common reasons CINV remains a problem are underuse of guideline-based prevention, delayed nausea after patients go home, and difficulty controlling nausea even when vomiting is prevented. This is relevant in India too, where access, cost, and differences between hospital protocols may affect which antiemetics are used.

Diagnosis / how it's measured

CINV is diagnosed clinically. There is no single blood test or scan that confirms it. Your oncology team usually identifies it from the timing of symptoms in relation to chemotherapy, the drugs you received, how severe the nausea is, whether vomiting occurred, and whether rescue medicines were needed.

Clinicians often think about these questions:

• Did symptoms start during the first 24 hours or later?
• Was the chemotherapy regimen high, moderate, low, or minimal emetic risk?
• Were preventive antiemetics given correctly?
• Is this breakthrough, delayed, or anticipatory CINV?
• Could another cause be contributing?

Other causes of nausea and vomiting must be considered, especially if symptoms are severe, unusual, or prolonged. These include bowel obstruction, infection, brain metastases, high calcium, liver problems, opioid side effects, constipation, gastritis, and dehydration. In cancer care, not every episode of vomiting after chemotherapy is automatically CINV.

Some centres use patient diaries or symptom scales to track nausea by day, because delayed symptoms are easy to underestimate once the patient has gone home.

When to see a clinician

Contact your oncology team promptly if you cannot keep fluids down, vomit repeatedly, feel dizzy, pass very little urine, or have signs of dehydration. You should also seek help if nausea or vomiting continues despite the medicines you were prescribed, or if symptoms start much later than expected.

Urgent assessment is important if vomiting is accompanied by severe abdominal pain, abdominal swelling, confusion, fever, blood in vomit, severe headache, or new neurological symptoms. These features can suggest causes other than routine CINV.

If you had poor control in one chemotherapy cycle, tell your team before the next cycle. Antiemetic plans can often be strengthened for future treatment. Patients should not change or add medicines on their own without checking with the oncology team, because some antiemetics interact with chemotherapy, steroids, sedatives, or other supportive drugs.

Limitations and open questions

Although prevention has improved a lot, CINV has not been eliminated. Delayed nausea, nausea without vomiting, and anticipatory symptoms remain difficult areas. Evidence supports several antiemetic combinations, but the best regimen can still vary by chemotherapy protocol, patient risk factors, prior response, and local availability.

Another limitation is that trial results often focus on vomiting and use of rescue medication, while patients may care most about persistent nausea, appetite loss, and day-to-day functioning. Evidence for behavioral and complementary approaches is mixed and generally less strong than for standard antiemetic drugs. These methods may help some people, but they should be used as add-ons, not substitutes, for guideline-based prevention.

Research continues on better prediction of who is most likely to develop CINV, how to improve delayed nausea control, and how to tailor antiemetic therapy more precisely. If you are receiving chemotherapy, the safest approach is to discuss symptoms early with your oncologist, oncology nurse, or pharmacist so the prevention plan can be adjusted before the next cycle.